IL6 and schizophrenia: This is consistent with recent work by Behrens and colleagues [18], [69] demonstrating that treatment with the NMDA antagonist, ketamine, results in increased interleukin-6 production, which in turn leads to reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase levels and to loss of interneuron phenotype analogous to that observed in patients with schizophrenia.